Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

NCT04774003 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
DRUG: Placebo
DRUG: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)

Sponsor

Novartis Pharmaceuticals